WO2002034760A3 - Compounds and methods - Google Patents

Compounds and methods Download PDF

Info

Publication number
WO2002034760A3
WO2002034760A3 PCT/US2001/051175 US0151175W WO0234760A3 WO 2002034760 A3 WO2002034760 A3 WO 2002034760A3 US 0151175 W US0151175 W US 0151175W WO 0234760 A3 WO0234760 A3 WO 0234760A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccr5
receptor
treatment
antagonists
copd
Prior art date
Application number
PCT/US2001/051175
Other languages
French (fr)
Other versions
WO2002034760A2 (en
Inventor
William E Bondinell
Michael J Neeb
Original Assignee
Smithkline Beecham Corp
William E Bondinell
Michael J Neeb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, William E Bondinell, Michael J Neeb filed Critical Smithkline Beecham Corp
Priority to AU2002235277A priority Critical patent/AU2002235277A1/en
Priority to EP01985647A priority patent/EP1343796A4/en
Publication of WO2002034760A2 publication Critical patent/WO2002034760A2/en
Publication of WO2002034760A3 publication Critical patent/WO2002034760A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

The invention relates to substituted urea compounds which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, all in mammals, by the use of substituted urea compounds which are CCR5 receptor antagonists. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators maybe useful in the treatment of HIV infection.
PCT/US2001/051175 2000-10-23 2001-10-23 Compounds and methods WO2002034760A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002235277A AU2002235277A1 (en) 2000-10-23 2001-10-23 Compounds and methods
EP01985647A EP1343796A4 (en) 2000-10-23 2001-10-23 Compounds and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24242700P 2000-10-23 2000-10-23
US60/242,427 2000-10-23

Publications (2)

Publication Number Publication Date
WO2002034760A2 WO2002034760A2 (en) 2002-05-02
WO2002034760A3 true WO2002034760A3 (en) 2003-01-23

Family

ID=22914746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051175 WO2002034760A2 (en) 2000-10-23 2001-10-23 Compounds and methods

Country Status (3)

Country Link
EP (1) EP1343796A4 (en)
AU (1) AU2002235277A1 (en)
WO (1) WO2002034760A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050165004A1 (en) * 2004-01-22 2005-07-28 Staffan Skogvall Bronchorelaxing compounds
WO2008095852A1 (en) * 2007-02-08 2008-08-14 Respiratorius Ab Bronchorelaxing arylamides
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
CN105101967B (en) * 2012-12-21 2019-06-28 雅培控股公司 As thrombocytin 5-HT2CThe benzazepines of receptors ligand and its application
US20210371388A1 (en) * 2020-05-12 2021-12-02 Baruch S. Blumberg Institute Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023769A2 (en) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Heterocyclic compounds possessing 5ht2c receptor antagonist activity
WO1998047885A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9724372D0 (en) * 1997-11-18 1998-01-14 Smithkline Beecham Plc Novel compounds
CA2304959A1 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
CA2338697A1 (en) * 1998-07-28 2000-02-10 Smithkline Beecham Corporation Compounds and methods
BR9912406A (en) * 1998-07-28 2001-04-24 Smithkline Beecham Corp Substituted anilide compounds and methods
AU3215500A (en) * 1999-01-25 2000-08-07 Smithkline Beecham Corporation Compounds and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023769A2 (en) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Heterocyclic compounds possessing 5ht2c receptor antagonist activity
WO1998047885A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1343796A4 *

Also Published As

Publication number Publication date
AU2002235277A1 (en) 2002-05-06
WO2002034760A2 (en) 2002-05-02
EP1343796A2 (en) 2003-09-17
EP1343796A4 (en) 2005-01-12

Similar Documents

Publication Publication Date Title
WO2004011427A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
WO2004010942A3 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
WO2004010943A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
IL133730A0 (en) Compounds and methods substituted benzanilides as ccr5 ligands
EP1140072A4 (en) Compounds and methods
AR013669A1 (en) COMPOUNDS AND METHODS
WO2006135385A3 (en) Antagonizing interleukin-21 receptor activity
ATE422496T1 (en) SUBSTITUTED PYRIDOÄ2,3-DÜPYRIMIDINE DERIVATIVES SUITABLE AS MEDICATIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
PE33495A1 (en) ISOXAZOLINE COMPOUND USEFUL AS AN ANTI-INFLAMMATOR AGENT
BRPI0507123A (en) compound, drug, use of a compound, and process for controlling a disorder or disease associated with crth2 activity in humans and animals
EP1000930A3 (en) Tachykinin antagonists
ES2139754T3 (en) 3-PHENYL-2-ISOXAZOLINES AS ANTI-INFLAMMATORY AGENTS.
TW200745108A (en) Condensed pyridine compound
SG155943A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
NO960811L (en) Carbocyclic and heterocyclic quinoline carboxylic acids with condensed rings which can be used as immune response suppressants
EP1156801A4 (en) Compounds and methods
UA103634C2 (en) Azaindazole compounds as ccr1 receptor antagonists
TW200738660A (en) Piperidinyl derivatives as modulators of chemokine receptor activity
WO2002034760A3 (en) Compounds and methods
WO2005079497A3 (en) Substituted fused bicyclic amines as modulators of chemokine receptor activity
Sahputra et al. Monocyte-derived peritoneal macrophages protect C57BL/6 mice against surgery-induced adhesions
WO2005042517A3 (en) Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
WO2004056770A3 (en) Piperidine derivatives useful as ccr5 antagonists
TW200745087A (en) CCR5 antagonists useful for treating HIV
ATE229952T1 (en) SUBSTITUTED N-METHYL-N-(4-(PIPERIDINE-1-YL)-2-ARYLBUTYL)-BENZAMIDE FOR THE TREATMENT OF ALLERGY DISEASES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001985647

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001985647

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001985647

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP